Business News • PR NewsWire • Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in women with HER2 positive advanced breast cancer

Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in women with HER2 positive advanced breast cancer

Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in women with HER2 positive advanced breast cancer

EAST HANOVER, N.J., June 2, 2013 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor® (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who...

View More : http://www.prnewswire.com/news-releases/novartis-pivotal-phase-iii-trial-shows-afinitor-significantly-delays-tumor-growt...

Releted News by prnewswire

Latest Jobs Data Released: Finance Jobs Make a Come-Back While Engineering Remains Resilient

Bariatric Surgery from Beverly Hills Physicians Goes Mainstream

Home Grown UAE Firm Continues to Win Market Share Against Multinational Firms…

Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor growth in women with HER2 positive advanced breast cancer

Avionics International 2014 to Run in Parallel with Abu Dhabi Air Expo Show

Women Foreign Workers Growing in Importance in the Middle East, Western Union-Sponsored Research Paper Finds